

# Anasept Antimicrobial Skin & Wound Care Products

Highly effective, FDA-cleared, non-cytotoxic, broad-spectrum antimicrobial skin & wound care products for clinically superior wound cleansing and wound bed preparation. There are no known microbial resistances to Anasept® including antibiotic resistant strains and multi drug-resistant organisms.

Anasept® products are also licensed by Health Canada.



bravidamedical.com

# Anasept Antimicrobial Skin & Wound Cleanser



# **Product Description**

Anasept® Antimicrobial Skin & Wound Cleanser is a clear, isotonic liquid that helps in the mechanical removal of the debris and foreign material from the application site. Dirt, debris and foreign materials are mechanically removed by the action of the fluid (Wound Cleanser) moving across the wound bed or application site. Anasept® Antimicrobial Skin & Wound Cleanser contains a broad-spectrum antimicrobial agent clinically proven to reduce bioburden levels and improve the rate of healing. Anasept® inhibits the growth of bacteria such as Acinetobacter baumannii, Clostridium difficile, Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, including antibiotic resistant Carbapenem Resistant E. Coli (CRE), Methicillin Resistant Staphylococcus aureus (MRSA) and Vancomycin resistant Enterococcus faecalis (VRE) that are commonly found in wound bed, as well as fungi, such as Candida albicans, Candida auris and Aspergillus niger.

#### **Indications**

#### Over-the-counter use:

Anasept® is intended for OTC use for mechanical cleansing and removal of dirt, debris and foreign material from skin abrasions, lacerations, minor irritations, cuts, exit sites and intact skin.

#### **Professional use:**

Anasept® is intended for use under the supervision of a healthcare professional for mechanical cleansing and removal of foreign material including microorganisms and debris from wounds such as stage I-IV pressure injuries, partial and full thickness wounds, diabetic foot ulcers, post-surgical wounds, first and second degree burns, grafted and donor sites.

#### Safety:

Anasept® has been subjected to rigorous safety testing at an independent FDA registered laboratory and shown to meet all criteria for safe use.

- Modified Primary Skin Irritation (FHSA method 7 day exposure with repeated insult to intact and abrade skin)
- Cytotoxicity (ISO Agarose Overlay method)
- Systemic toxicity (ISO Acute Systemic Toxicity)
- ISO Sensitization Study

# Clinical Areas for Anasept® Use

Indicated for all wounds except ophthalmic use. Effectively used in all patient care areas including - Acute Care Hospital Inpatient Units, Critical and Intensive Care Areas, Pediatrics, Surgery Centers and Operating Rooms, Emergency Rooms, Trauma Centers, Dermatology, Wound Clinics, Burn Centers, Vascular Access for Catheter and Drive Line Sites, Infusion Clinics, Dialysis Clinics, Physician and Outpatient Clinics, Long Term Care and Post-Acute Areas, Physical and Occupational Therapy Clinics, Sports Medicine and Rehab Units, Skilled Nursing Facilities, Nursing Homes, and Home Health Care.

# **Exceptional Benefits**

- FDA cleared; broad-spectrum antimicrobial
- Tissue compatible isotonic solution
- Non-cytotoxic, non-irritating, non-toxic, non-sensitizing as proven by FDA certified laboratories
- Ideal alternative for CHG sensitive patients
- Clinically proven to safely reduce bioburden levels and improve the rate of healing
- No known microbial resistances to bacteria, fungus/ yeast, viruses, spores including multi drug-resistant organisms (MDRO)
- Outstanding wound odor control
- Latex Free
- 2 year shelf life when stored at room temperature up to 25°C (77°F) and active for 14 weeks after initial use





## Time Kill Studies for Anasept® Antimicrobial Skin & Wound Cleanser

In the time kill studies below, extremely high concentrations of pathogenic microorganisms were exposed to Anasept® over the course of precisely timed intervals in the presence of an interfering substance that simulated the organic load condition of the wound environment and is known to inhibit the action of antimicrobial agents.

| 1  | Table of Microbial Activity    |                  |                      |                  |
|--|--------------------------------|------------------|----------------------|------------------|
| Test Organisms                                     | Initial Microorganism Count/ML | I                | Exposure time        | / % Kill         |
|  |                                | 30 9             | 5 1 m                | 5 m              |
| Pathogenic Bacteria                                |                                |                  |                      |                  |
| Acinetobacter baumannii                            | 107                            | _                | 99.089%              | 99.98%           |
| Carbapenem Resistant E. coli (CRE)                 | 10 <sup>6</sup>                | 99.999%          | 99.999%              | 99.999%          |
| Clostridium difficile                              | 10 <sup>5</sup>                | 100%             | 100%                 | 100%             |
| Escherichia coli                                   | 107                            | 100%             | 100%                 | 100%             |
| Methicillin Resistant Staphylococcus aureus (MRSA) | 107                            | 100%             | 100%                 | 100%             |
| Proteus mirabilis                                  | 108                            | 99.998%          | 100%                 | 100%             |
| Pseudomonas aeruginosa                             | 107                            | 100%             | 100%                 | 100%             |
| Serratia marcescens                                | 107                            | 100%             | 100%                 | 100%             |
| Staphylococcus aureus                              | 107                            | 100%             | 100%                 | 100%             |
| Vancomycin Resistant Enterococcus faecalis (VRE)   | 107                            | 100%             | 100%                 | 100%             |
| Pathogenic Fungi                                   |                                |                  |                      |                  |
| Aspergillus niger                                  | 107                            | 99.99%           | 99.9999%             | 100%             |
| Candida albicans                                   | 107                            | 99.1%            | 99.9%                | 100%             |
| Candida auris                                      | 105                            | 99.1%            | >99.9%               | >99.9%           |
| Table of Sporicidal Activity                       |                                |                  |                      |                  |
| Test Spore   | Initial Spore<br>Count/ML      | Exposure<br>Time | Percent<br>Reduction | Log<br>Reduction |
| Clostridium difficile - spore                      | 10 <sup>6</sup>                | 15 m             | 99.999%              | >5.7             |
|  | Table of Virusidal Activity    |                  |                      |                  |

| Table of Virucidal Activity                |                           |                  |                      |                  |
|--|---------------------------|------------------|----------------------|------------------|
| Test Virus                                 | Initial Virus<br>Count/ML | Exposure<br>Time | Percent<br>Reduction | Log<br>Reduction |
| HIV-Type 1 (Human Immuno Deficiency Virus) | 106                       | 5 m              | 99.997%              | ≥4.5             |
| SARS Related Coronavirus 2                 | 10 <sup>5.25</sup>        | 5 m              | ≥99.98%              | ≥3.75            |
| Human Coronavirus Strain 229E              | 105.5                     | 5 m              | ≥99.99%              | ≥4.0             |





# Anasept Antimicrobial Skin & Wound Gel



# **Product Description**

Anasept<sup>®</sup> Antimicrobial Skin & Wound Gel is a clear, amorphous, isotonic hydrogel that helps maintain a moist wound environment that is conducive to healing, by either absorbing wound exudate or donating moisture while delivering a unique blend of .057% broad-spectrum antimicrobial sodium hypochlorite.

Anasept Gel inhibits the growth of bacteria such as Acinetobacter baumannii, Clostridium difficile, Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, including antibiotic resistant Carbapenem Resistant E. Coli (CRE), Methicillin Resistant Staphylococcus aureus (MRSA) and Vancomycin resistant Enterococcus faecalis (VRE) that are commonly found in wound bed, as well as fungi, such as Candida albicans, Candida auris and Aspergillus niger.

#### **Indications**

#### Over-the-counter use:

Anasept Gel is intended for OTC use for management of skin abrasions, lacerations, minor irritations, cuts, exit sites and intact skin.

#### **Professional use:**

Anasept Gel is intended for use under the supervision of a healthcare professional in the management of wounds such as stage I-IV pressure injuries, partial and full thickness wounds, diabetic foot and leg ulcers, post-surgical wounds, first and second-degree burns, grafted and donor sites.

#### Safety:

Anasept® has been subjected to rigorous safety testing at an independent FDA registered laboratory and shown to meet all criteria for safe use.

- Modified Primary Skin Irritation (FHSA method 7 day exposure with repeated insult to intact and abrade skin)
- Cytotoxicity (ISO Agarose Overlay method)
- Systemic toxicity (ISO Acute Systemic Toxicity)
- ISO Sensitization Study

# Clinical Areas for Anasept® Gel Use

Excellent for dry to minimally exudating wounds. Effectively used in all patient care areas including - Acute Care Hospital Inpatient Units, Critical and Intensive Care Areas, Pediatrics, Surgery Centers and Operating Rooms, Emergency Rooms, Trauma Centers, Dermatology, Wound Clinics, Burn Centers, Vascular Access for Catheter and Drive Line Sites, Infusion Clinics, Dialysis Clinics, Physician and Outpatient Clinics, Long Term Care and Post-Acute Areas, Physical and Occupational Therapy Clinics, Sports Medicine and Rehab Units, Skilled Nursing Facilities, Nursing Homes, and Home Health Care.

# **Exceptional Benefits**

- FDA cleared; broad-spectrum antimicrobial
- Tissue compatible isotonic solution
- Non-cytotoxic, non-irritating, non-toxic, non-sensitizing as proven by FDA certified laboratories
- No known microbial resistances to bacteria, fungus/ yeast, viruses, spores including multi drug-resistant organisms (MDRO)
- Clinically proven to safely reduce bioburden levels and improve the rate of healing
- Promotes quick and effective autolytic debridement of non-viable tissue
- Outstanding wound odor control
- Latex Free
- 2 year shelf life when stored at room temperature up to 25°C (77°F) and active for 14 weeks after initial use
- Medicare Reimbursement HCPCS Code # A6248





## Time Kill Studies for Anasept® Antimicrobial Skin & Wound Gel

In the time kill studies below, extremely high concentrations of pathogenic microorganisms were exposed to Anasept® over the course of precisely timed intervals in the presence of an interfering substance that simulated the organic load condition of the wound environment and is known to inhibit the action of antimicrobial agents.

|  | Table of Microbial Activity    |         |                  |                      |                  |
|--|--------------------------------|---------|------------------|----------------------|------------------|
| Test Organisms                                     | Initial Microorganism<br>Count | 1m      | Exposure<br>3m   | time / % Kill<br>5m  | 10 m             |
| Pathogenic Bacteria                                |                                |         |                  |                      |                  |
| Acinetobacter baumannii                            | 107                            | 98.56%  | 99.99%           | 99.998%              | 99.9999%         |
| Carbapenem Resistant E. coli (CRE)                 | 10 <sup>6</sup>                | 99.999% | 99.999%          | 99.999%              | 99.999%          |
| Clostridium difficile                              | 105                            | 100%    | 100%             | 100%                 | 100%             |
| Escherichia coli                                   | 107                            | 99.25%  | 99.986%          | 99.9995%             | 100%             |
| Methicillin Resistant Staphylococcus aureus (MRSA) | 107                            | 100%    | 100%             | 100%                 | 100%             |
| Proteus mirabilis                                  | 10 <sup>8</sup>                | 99.888% | 99.998%          | 99.9998%             | 100%             |
| Pseudomonas aeruginosa                             | 107                            | 99.996% | 100%             | 100%                 | 100%             |
| Serratia marcescens                                | 107                            | 100%    | 100%             | 100%                 | 100%             |
| Staphylococcus aureus                              | 107                            | 100%    | 100%             | 100%                 | 100%             |
| Vancomycin Resistant Enterococcus faecalis (VRE)   | 107                            | 100%    | 100%             | 100%                 | 100%             |
| Pathogenic Fungi                                   |                                |         |                  |                      |                  |
| Aspergillus niger                                  | 10 <sup>6</sup>                | 100%    | 100%             | 100%                 | 100%             |
| Candida albicans                                   | 10 <sup>6</sup>                | 100%    | 100%             | 100%                 | 100%             |
| Candida auris                                      | 105                            | 99.9%   | >99.9%           | >99.9%               | N/A              |
|  | Table of Sporicidal Activity   |         |                  |                      |                  |
| Test Spore   | Initial Spore<br>Count/ML      |         | Exposure<br>Time | Percent<br>Reduction | Log<br>Reduction |
| Clostridium difficile - spore                      | 106                            |         | 15 m             | 99.9%                | >4.0             |
| Table of Virucidal Activity                        |                                |         |                  |                      |                  |
| Test Virus   | Initial Virus<br>Count/ML      |         | Exposure<br>Time | Percent<br>Reduction | Log<br>Reduction |
| HIV-Type 1 (Human Immuno Deficiency Virus)         | 106                            |         | 5 m              | 99.97%               | ≥3.5             |
| SARS Related Coronavirus 2                         | 10 <sup>5.25</sup>             |         | 5 m              | ≥99.98%              | ≥3.75            |
| Human Coronavirus Strain 229E                      | 10 <sup>5.5</sup>              |         | 5 m              | ≥99.9%               | ≥3.0             |





# Anasept Antimicrobial Wound Irrigation Solution

Anasept Antimicrobial Wound Irrigation Solution is a breakthrough in Negative Pressure Wound Therapy (NPWT). Based on Bravida Medical's highly effective and FDA cleared, Anasept Antimicrobial Skin & Wound Cleanser, Anasept Antimicrobial Wound Irrigation Solution is specifically designed for NPWT Systems.

# **Product description**

Anasept® Antimicrobial Wound Irrigation Solution is a completely clear, isotonic solution that helps in the mechanical removal of debris from the application site while delivering non-cytotoxic, broad-spectrum antimicrobial activity to wound bed via NPWT System equipped with instillation or infusion capability.

Anasept® Antimicrobial Wound Irrigation Solution inhibits the growth of bacteria such as: Acinetobacter baumannii, Clostridium difficile, Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Staphylococcus aureus, Serratia marcescens, Carbapenem Resistant Escherichia coli (CRE), Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococcus faecalis (VRE), as well as fungi such as: Candida albicans, Candida auris and Aspergillus niger that are commonly found in the wound bed. See detailed Time Kill Studies data on next page which illustrates Anasept's excellent bactericidal, fungicidal, sporicidal, and virucidal properties without damaging healthy tissue and cells.

Easy to use spikeable container with an integrated hanger that is quickly attached to an I.V. Pole or Negative Pressure Wound Therapy Systems and can be used with most NPWT Systems that are available with instillation or infusion capability.

# Safety

Anasept® has been subjected to rigorous safety testing at an independent FDA registered laboratory and shown to meet all criteria for safe use.

- Clinically Tested: Anasept® is clinically proven to reduce bioburden levels and improve the rate of healing
- Non-Flammable: can safely be used in hyperbaric chambers.
- **Shelf Life:** Stable for 2 years from date of manufacture, when maintained at normal room temperature up to 25°C (77°F).

Approved for use with the Veraflo™ Negative Pressure Wound Therapy system



Easy to use spikeable container with an integrated hanger





## Time Kill Studies for Anasept® Antimicrobial Wound Irrigation Solution

In the time kill studies below, extremely high concentrations of pathogenic microorganisms were exposed to Anasept® over the course of precisely timed intervals in the presence of an interfering substance that simulated the organic load condition of the wound environment and is known to inhibit the action of antimicrobial agents.

|  | Table of Microbial Activity    |                  |                      |                  |
|--|--------------------------------|------------------|----------------------|------------------|
| Test Organisms                                     | Initial Microorganism Count/ML | I                | Exposure time        | / % Kill         |
|  |                                | 30 :             | s 1 m                | 5 m              |
| Pathogenic Bacteria                                |                                |                  |                      |                  |
| Acinetobacter baumannii                            | 107                            | -                | 99.089%              | 99.98%           |
| Carbapenem Resistant E. coli (CRE)                 | 106                            | 99.999%          | 99.999%              | 99.999%          |
| Clostridium difficile                              | 10⁵                            | 100%             | 100%                 | 100%             |
| Escherichia coli                                   | 107                            | 100%             | 100%                 | 100%             |
| Methicillin Resistant Staphylococcus aureus (MRSA) | 107                            | 100%             | 100%                 | 100%             |
| Proteus mirabilis                                  | 10 <sup>8</sup>                | 99.998%          | 100%                 | 100%             |
| Pseudomonas aeruginosa                             | 107                            | 100%             | 100%                 | 100%             |
| Serratia marcescens                                | 107                            | 100%             | 100%                 | 100%             |
| Staphylococcus aureus                              | 107                            | 100%             | 100%                 | 100%             |
| Vancomycin Resistant Enterococcus faecalis (VRE)   | 107                            | 100%             | 100%                 | 100%             |
| Pathogenic Fungi                                   |                                |                  |                      |                  |
| Aspergillus niger                                  | 107                            | 99.99%           | 99.9999%             | 100%             |
| Candida albicans                                   | 107                            | 99.1%            | 99.9%                | 100%             |
| Candida auris                                      | 10⁵                            | 99.1%            | >99.9%               | >99.9%           |
| Table of Sporicidal Activity                       |                                |                  |                      |                  |
| Test Spore   | Initial Spore<br>Count/ML      | Exposure<br>Time | Percent<br>Reduction | Log<br>Reduction |
| Clostridium difficile - spore                      | 106                            | 15 m             | 99.999%              | >5.7             |
|  | Table of Virucidal Activity    |                  |                      |                  |

| Tal  | ble of Virucidal Activity |                  |                      |                  |
|--|---------------------------|------------------|----------------------|------------------|
| Test Virus                                 | Initial Virus<br>Count/ML | Exposure<br>Time | Percent<br>Reduction | Log<br>Reduction |
| HIV-Type 1 (Human Immuno Deficiency Virus) | 10 <sup>6</sup>           | 5 m              | 99.997%              | ≥4.5             |
| SARS Related Coronavirus 2                 | 10 <sup>5.25</sup>        | 5 m              | ≥99.98%              | ≥3.75            |
| Human Coronavirus Strain 229E              | <b>10</b> <sup>5.5</sup>  | 5 m              | ≥99.99%              | ≥4.0             |





# **Ordering Information**

Available through your preferred distributor or direct via Bravida Medical. Contact Bravida Medical with questions and GPO contract pricing.

#### Anasept® Antimicrobial Skin & Wound Cleanser

| Product and Catalog No.  | Size  | Case Qty |
|--------------------------|-------|----------|
| 4004C (Dispensing Cap)   | 4 oz  | 24       |
| 4008C (Dispensing Cap)   | 8 oz  | 12       |
| 4004SC (Finger Sprayer)  | 4 oz  | 12       |
| 4008SC (Finger Sprayer)  | 8 oz  | 12       |
| 4008TC (Trigger Sprayer) | 8 oz  | 12       |
| 4012SC (Trigger Sprayer) | 12 oz | 12       |
| 4016C (Dispensing Cap)   | 15 oz | 12       |

### Anasept® Antimicrobial Skin & Wound Gel

| Product and Catalog No. | Size   | Case Qty |
|-------------------------|--------|----------|
| 5015G (Tube)            | 1.5 oz | 12       |
| 5003G (Tube)            | 3 oz   | 12       |

# Anasept® Antimicrobial Wound Irrigation Solution

| Product and Catalog No. | Size  | Case Qty |
|-------------------------|-------|----------|
| 4160IC (Spikeable cap)  | 16 oz | 12       |

#### Reference List

- 1. https://www.accessdata.fda.gov/cdrh\_docs/pdf7/K073547.pdf
- 2. https://static.webareacontrol.com/CommonFile/ Anacapa%20Anasept%20Antimicrobial%20Skin%20And%20Wound%20Cleanser\_Safety%20Data%20Sheet.pdf
- 3. Data on File. Bravida Medical. FDA Accredited Lab Facilities, Analytical Lab Group Midwest, Accuratus Lab Services, ATS Labs, BioScreen Testing Services, and Microbiological Consultants. 2008-2024.
- 4. Lindfors J. A comparison of an antimicrobial wound cleanser to normal saline in reduction of bioburden and its effect on wound healing. Ostomy Wound Manage. 2004 Aug;50(8):28-41. PMID: 15356367.
- 5. Cytotoxicity Study Using the Agarose Overlay Method. Anasept Skin and Wound Antiseptic. NAMSA, Irvine, CA. Lot#EB2300C. Data on file. Bravida Medical.

To learn more about Bravida solutions please visit bravidamedical.com or call 888.551.0188 Bravida Medical 2571 Kaneville Ct. Geneva, IL 60134

©Bravida Medical. All rights reserved.

Anasept® is a registered trademark of Anacapa Technologies, Inc.

To see other Bravida Brands and Products, **Scan Here:** 

